- Home
- USIO vs CING Comparison
USIO vs CING Comparison
Compare USIO & CING Stocks: Price Trends, ML Decisions, Charts, Trends, Technical Analysis and more.
Current Price
Company Overview
Basic Information| Metric | USIO | CING |
|---|---|---|
| Founded | 1998 | 2012 |
| Country | United States | United States |
| Employees | N/A | N/A |
| Industry | Investment Bankers/Brokers/Service | Biotechnology: Pharmaceutical Preparations |
| Sector | Finance | Health Care |
| Exchange | Nasdaq | Nasdaq |
| Market Cap | 36.6M | 40.5M |
| IPO Year | 1999 | N/A |
Fundamental Metrics
Financial Performance| Metric | USIO | CING |
|---|---|---|
| Price | $1.30 | $6.97 |
| Analyst Decision | Strong Buy | Strong Buy |
| Analyst Count | 1 | 3 |
| Target Price | $4.00 | ★ $31.33 |
| AVG Volume (30 Days) | 32.3K | ★ 313.0K |
| Earning Date | 05-13-2026 | 01-01-0001 |
| Dividend Yield | N/A | N/A |
| EPS Growth | ★ 700.00 | N/A |
| EPS | N/A | ★ N/A |
| Revenue | ★ $28,200,535.00 | N/A |
| Revenue This Year | $6.30 | N/A |
| Revenue Next Year | $11.86 | N/A |
| P/E Ratio | ★ N/A | N/A |
| Revenue Growth | ★ 12.69 | N/A |
| 52 Week Low | $1.24 | $3.20 |
| 52 Week High | $2.02 | $7.92 |
Technical Indicators
Market Signals| Indicator | USIO | CING |
|---|---|---|
| Relative Strength Index (RSI) | 39.70 | 59.70 |
| Support Level | N/A | $3.58 |
| Resistance Level | $1.42 | $7.92 |
| Average True Range (ATR) | 0.04 | 0.50 |
| MACD | -0.00 | -0.01 |
| Stochastic Oscillator | 10.53 | 86.43 |
Price Performance
Historical ComparisonAbout USIO Usio Inc.
Usio Inc is a United States-based company that provides integrated electronic payment services, including credit and debit card-based processing services and transaction processing via the Automated Clearing House, or ACH network to billers and retailers. The Company also has an additional wholly-owned subsidiary, which is the entity for Output Solutions operations.
About CING Cingulate Inc.
Cingulate Inc is a clinical-stage biopharmaceutical company utilizing its proprietary precision timed-release drug delivery platform to build and advance a pipeline of next-generation pharmaceutical products designed to improve the lives of patients suffering from frequently diagnosed conditions characterized by burdensome daily dosing regimens and suboptimal treatment outcomes. The company focuses on the treatment of Attention Deficit/Hyperactivity Disorder (ADHD) and anxiety, and identifying and evaluating additional therapeutic area to use PTR technology to develop future product candidates.